GLYCOPEDIA

References

Abdu-allah, H. H. M., Watanabe, K., Completo, G. C., Sadagopan, M., Hayashizaki, K., Takaku, C., Tamanaka, T., Takematsu, H., Kozutsumi, Y., Paulson, J. C., Tsubata, T., Ando, H., Ishida, H., & Kiso, M. (2011). CD22-Antagonists with nanomolar potency : the synergistic effect of hydrophobic groups at C-2 and C-9 of sialic acid scaffold. Bioorganic & Medicinal Chemistry, 19(6), 1966–1971. https://doi.org/10.1016/j.bmc.2011.01.060

Abdu-Allah, H. H. M., Wu, S. C., Lin, C. H., & Tseng, Y. Y. (2020). Design, synthesis and molecular docking study of α-triazolylsialosides as non-hydrolyzable and potent CD22 ligands. European Journal of Medicinal Chemistry, 208, 112707. https://doi.org/10.1016/j.ejmech.2020.112707

Adeel, K., Fergusson, N. J., Shorr, R., Atkins, H., & Hay, K. A. (2021). Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies : a protocol for a systematic review and meta-analysis. Systematic Reviews, 10(1), 35. https://doi.org/10.1186/s13643-021-01588-7

Adeniji, O. S., Kuri-Cervantes, L., Yu, C., Xu, Z., Ho, M., Chew, G. M., Shikuma, C., Tomescu, C., George, A. F., Roan, N. R., Ndhlovu, L. C., Liu, Q., Muthumani, K., Weiner, D. B., Betts, M. R., Xiao, H., & Abdel-Mohsen, M. (2021). Siglec-9 defines and restrains a natural killer subpopulation highly cytotoxic to HIV-infected cells. PLoS Pathogens, 17(11), e1010034. https://doi.org/10.1371/journal.ppat.1010034

Ali, S. R., Fong, J. J., Carlin, A. F., Busch, T. D., Linden, R., Angata, T., Areschoug, T., Parast, M., Varki, N., Murray, J., Nizet, V., & Varki, A. (2014). Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group B Streptococcus. Journal of Experimental Medicine, 211(6), 1231–1242. https://doi.org/10.1084/jem.20131853

Altrichter, S., Staubach, P., Pasha, M., Rasmussen, H., Singh, B., Chang, A., Bernstein, J. Siebenhaar, F., & Maurer, M. (2019). Efficacy and safety data of AK002, an anti-siglec-8 monoclonal antibody, in patients with multiple forms of uncontrolled chronic urticaria (CU) : Results from an open-label phase 2a study. Allergy, 74, 117–129.

Angata, T., Y., Nakamura, K., & Nakamura, M. (2007). Siglec-15 : an immune system Siglec conserved throughout vertebrate evolution. Glycobiology, 17(8), 838–846. https://doi.org/10.1093/glycob/cwm049

Angata, T. (2006). Molecular diversity and evolution of the Siglec family of cell-surface lectins. Molecular Diversity, 10(4), 555–566. https://doi.org/10.1007/s11030-006-9029-1

Angata, T. (2020). Siglec-15 : a potential regulator of osteoporosis, cancer, and infectious diseases. Journal of Biomedical Science, 27(1), 10. https://doi.org/10.1186/s12929-019-0610-1

Angata, T., Hayakawa, T., Yamanaka, M., Varki, A., & Nakamura, M. (2006). Discovery of Siglec‐14, a novel sialic acid receptor undergoing concerted evolution with Siglec‐5 in primates. The FASEB Journal, 20(12), 1964–1973. https://doi.org/10.1096/fj.06-5800com

Angata, T.,, Kerr, S. C., Greaves, D. R., Varki, N. M., Crocker, P. R., & Varki, A. (2002). Cloning and characterization of human Siglec-11. Journal of Biological Chemistry, 277(27), 24466–24474. https://doi.org/10.1074/jbc.M202833200

Angata, Takashi, Margulies, E. H., Green, E. D., & Varki, A. (2004). Large-scale sequencing of the CD33-related Siglec gene cluster in five mammalian species reveals rapid evolution by multiple mechanisms. Proc. Natl. Acad. Sci., 101(36), 13251–13256. https://doi.org/10.1073/pnas.0404833101

Angata, T., Nycholat, C. M., & Macauley, M. S. (2015). Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches. Trends in Pharmacological Sciences, 36(10), 645–660. https://doi.org/10.1016/j.tips.2015.06.008

Attrill, H., Imamura, A., Sharma, R. S., Kiso, M., Crocker, P. R., & Van Aalten, D. M. F. (2006). Siglec-7 undergoes a major conformational change when complexed with the α(2,8)-disialylganglioside GT1b. Journal of Biological Chemistry, 281(43), 32774–32783. https://doi.org/10.1074/jbc.M601714200

Barbay, S., Plautz, E. J., Zoubina, E., Frost, S. B., Cramer, S. C., & Nudo, R. J. (2015). Effects of Postinfarct Myelin-Associated Glycoprotein Antibody Treatment on Motor Recovery and Motor Map Plasticity in Squirrel Monkeys. Stroke, 46(6), 1620–1625. https://doi.org/10.1161/STROKEAHA.114.008088

Barkal, A. A., Brewer, R. E., Markovic, M., Kowarsky, M., Barkal, S. A., Zaro, B. W., Krishnan, V., Hatakeyama, J., Dorigo, O., Barkal, L. J., & Weissman, I. L. (2019). CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature, 572(7769), 392–396. https://doi.org/10.1038/s41586-019-1456-0

Benmerzoug, S., Chevalier, M. F., Verardo, M., Nguyen, S., Cesson, V., Schneider, A. K., Dartiguenave, F., Rodrigues-Dias, S. C., Lucca, I., Jichlinski, P., Roth, B., Nardelli-Haefliger, D., & Derré, L. (2021). Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients. European Urology Focus, S2405-4569, Online ahead of print. https://doi.org/10.1016/j.euf.2021.06.001

Bhattacherjee, A., Rodrigues, E., Jung, J., Luzentales-Simpson, M., Enterina, J. R., Galleguillos, D., St. Laurent, C. D., Nakhaei-Nejad, M., Fuchsberger, F. F., Streith, L., Wang, Q., Kawasaki, N., Duan, S., Bains, A., Paulson, J. C., Rademacher, C., Giuliani, F., Sipione, S., & Macauley, M. S. (2019). Repression of phagocytosis by human CD33 is not conserved with mouse CD33. Communications Biology, 2, 450. https://doi.org/10.1038/s42003-019-0698-6

Biesen, R., Demir, C., Barkhudarova, F., Grün, J. R., Steinbrich-Zöllner, M., Backhaus, M., Häupl, T., Rudwaleit, M., Riemekasten, G., Radbruch, A., Hiepe, F., Burmester, G. R., & Grützkau, A. (2008). Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum., 58(4), 1136–1145. https://doi.org/10.1002/art.23404

Blixt, O., Collins, B. E., van den Nieuwenhof, I. M., Crocker, P. R., & Paulson, J. C. (2003). Sialoside specificity of the siglec family assessed using novel multivalent probes : identification of potent inhibitors of myelin-associated glycoprotein. The Journal of Biological Chemistry, 278(33), 31007–31019. https://doi.org/10.1074/jbc.M304331200

Bochner, B. S., Alvarez, R. A., Mehta, P., Bovin, N. V, Blixt, O., White, J. R., & Schnaar, R. L. (2005). Glycan Array Screening Reveals a Candidate Ligand for Siglec-8. The Journal of Biological Chemistry, 280(6), 4307–4312. https://doi.org/10.1074/jbc.M412378200

Bornhöfft, K. F., Goldammer, T., Rebl, A., & Galuska, S. P. (2018). Siglecs : A journey through the evolution of sialic acid-binding immunoglobulin-type lectins. Developmental and Comparative Immunology, 86, 219–231. https://doi.org/10.1016/j.dci.2018.05.008

Briard, J. G., Jiang, H., Moremen, K. W., MacAuley, M. S., & Wu, P. (2018). Cell-based glycan arrays for probing glycan-glycan binding protein interactions. Nature Communications, 9(1), 880. https://doi.org/10.1038/s41467-018-03245-5

Brinkman-Van Der linden, E. C. M., Hurtado-Ziola, N., Hayakawa, T., Wiggleton, L., Benirschke, K., Varki, A., & Varki, N. (2007). Human-specific expression of Siglec-6 in the placenta. Glycobiology, 17(9), 922–931. https://doi.org/10.1093/glycob/cwm065

Büll, C., den Brok, M. H., & Adema, G. J. (2014). Sweet escape : Sialic acids in tumor immune evasion. Biochimica et Biophysica Acta, 1846(1), 238–246. https://doi.org/10.1016/j.bbcan.2014.07.005

Büll, C., Heise, T., Adema, G. J., & Boltje, T. J. (2016). Sialic Acid Mimetics to Target the Sialic Acid–Siglec Axis. Trends in Biochemical Sciences, 41(6), 519–531. https://doi.org/10.1016/j.tibs.2016.03.007

Büll, C., Heise, T., van Hilten, N., Pijnenborg, J. F. A., Bloemendal, V. R. L. J., Gerrits, L., Kers-Rebel, E. D., Ritschel, T., den Brok, M. H., Adema, G. J., & Boltje, T. J. (2017). Steering Siglec–Sialic Acid Interactions on Living Cells using Bioorthogonal Chemistry. Angewandte Chemie - International Ed. in English, 56(12), 3309–3313. https://doi.org/10.1002/anie.201612193

Cao, H., Lakner, U., de Bono, B., Traherne, J. A., Trowsdale, J., & Barrow, A. D. (2008a). SIGLEC16 encodes a DAP12-associated receptor expressed in macrophages that evolved from its inhibitory counter- part SIGLEC11 and has functional and non-functional alleles in humans. European Journal of Immunology, 38(8), 2303–2315. https://doi.org/10.1002/eji.200738078

Cao, H., Lakner, U., de Bono, B., Traherne, J., Trowsdale, J., & Barrow, A. (2008b). SIGLEC16 encodes a DAP12-associated receptor expressed in macrophages that evolved from its inhibitory counter- part SIGLEC11 and has functional and non-functional alleles in humans. European Journal of Immunology, 38(8), 2303–2315. https://doi.org/10.1002/eji.200738078

Carlin, A. F., Chang, Y. C., Areschoug, T., Lindahl, G., Hurtado-Ziola, N., King, C. C., Varki, A., & Nizet, V. (2009). Group B Streptococcus suppression of phagocyte functions by protein-mediated engagement of human Siglec-5. Journal of Experimental Medicine, 206(8), 1691–1699. https://doi.org/10.1084/jem.20090691

Chang, Y. C., & Nizet, V. (2014). The interplay between Siglecs and sialylated pathogens. Glycobiology, 24(9), 818–825. https://doi.org/10.1093/glycob/cwu067

Chang, Y., & Nizet, V. (2020). Siglecs at the Host–Pathogen Interface. Advances in Experimental Medicine and Biology, 1204, 197–214. https://doi.org/10.1007/978-981-15-1580-4_8

Chang, Y., Olson, J., Louie, A., Crocker, P. R., Varki, A., & Nizet, V. (2014). Role of macrophage sialoadhesin in host defense against the sialylated pathogen group B Streptococcus. Journal of Molecular Medicine, 92(9), 951–959. https://doi.org/10.1007/s00109-014-1157-y

Chen, W. C., Completo, G. C., Sigal, D. S., Crocker, P. R., Saven, A., & Paulson, J. C. (2010). In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood, 115(23), 4778–4786. https://doi.org/10.1182/blood-2009-12-257386

Chen, Z., Bai, F. F., Han, L., Zhu, J., Zheng, T., Zhu, Z., & Zhou, L.-F. (2018). Targeting neutrophils in severe asthma via Siglec-9. International Archives of Allergy and Immunology, 175(1–2), 5–15. https://doi.org/10.1159/000484873

Clark, E. A., & Giltiay, N. V. (2018). CD22  : A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity. Frontiers in Immunology, 9, 2235. https://doi.org/10.3389/fimmu.2018.02235

Collins, B. E., Blixt, O., DeSieno, A. R., Bovin, N., Marth, J. D., & Paulson, J. C. (2004). Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. Proceedings of the National Academy of Sciences of the United States of America, 101(16), 6104–6109. https://doi.org/10.1073/pnas.0400851101

Collins, B. E., Blixt, O., Han, S., Duong, B., Li, H., Nathan, J. K., Bovin, N., & Paulson, J. C. (2006). High-Affinity Ligand Probes of CD22 Overcome the Threshold Set by cis Ligands to Allow for Binding, Endocytosis, and Killing of B Cells. The Journal of Immunology, 177(5), 2994–3003. https://doi.org/10.4049/jimmunol.177.5.2994

Cornish, A. L., Freeman, S., Forbes, G., Ni, J., Zhang, M., Cepeda, M., Gentz, R., Augustus, M., Carter, K. C., & Crocker, P. R. (1998). Characterization of Siglec-5, a novel glycoprotein expressed on myeloid cells related to CD33. Blood, 92(6), 2123–2132. https://doi.org/10.1182/blood.v92.6.2123

Cramer, S. C., Enney, L. A., Russell, C. K., Simeoni, M., & Thompson, T. R. (2017). Proof-of-Concept Randomized Trial of the Monoclonal Antibody GSK249320 Versus Placebo in Stroke Patients. Stroke, 48(3), 692–698. https://doi.org/10.1161/STROKEAHA.116.014517

Crocker, P.R., Kelm, S., Dubois, C., Martin, B., McWilliam, A. S., Shotton, D. M., Paulson, J. C., & Gordon, S. (1991). Purification and properties of sialoadhesin, a sialic acid-binding receptor of murine tissue macrophages. The EMBO Journal, 10(7), 1661–1669. https://doi.org/10.1002/j.1460-2075.1991.tb07689.x

Crocker, P.R, Mucklow, S., Bouckson, V., McWilliam, A., Willis, A. C., Gordon, S., Milon, G., Kelm, S., & Bradfield, P. (1994). Sialoadhesin, a macrophage sialic acid binding receptor for haemopoietic cells with 17 immunoglobulin-like domains. EMBO J, 13(19), 4490–4503.

Crocker, P.R., McMillan, S. J., & Richards, H. E. (2012). CD33-related siglecs as potential modulators of inflammatory responses. Annals of the New York Academy of Sciences, 1253, 102–111. https://doi.org/10.1111/j.1749-6632.2011.06449.x

Crocker, P.R., Paulson, J. C., & Varki, A. (2007). Siglecs and their roles in the immune system. Nature Reviews Immunology, 7(4), 255–266. https://doi.org/10.1038/nri2056

Crocker, P.R, Vinson, M., Kelm, S., & Drickamer, K. (1999). Molecular analysis of sialoside binding to sialoadhesin by NMR and site-directed mutagenesis. Biochemical Journal, 341(Pt. 2), 355–361.

Daly, J., Carlsten, M., & O’Dwyer, M. (2019). Sugar free : Novel immunotherapeutic approaches targeting siglecs and sialic acids to enhance natural killer cell cytotoxicity against cancer. Frontiers in Immunology, 10, 1047. https://doi.org/10.3389/fimmu.2019.01047

Delaveris, C. S., Wilk, A. J., Riley, N. M., Stark, J. C., Yang, S. S., Rogers, A. J., Ranganath, T., Nadeau, K. C., Blish, C. A., & Bertozzi, C. R. (2021). Synthetic Siglec-9 Agonists Inhibit Neutrophil Activation Associated with COVID-19. ACS Central Science, 7(4), 650–657. https://doi.org/10.1021/acscentsci.0c01669

Dellon, E. S., Peterson, K. A., Murray, J. A., Falk, G. W., Gonsalves, N., Chehade, M., Genta, R. M., Leung, J., Khoury, P., Klion, A. D., Hazan, S., Vaezi, M., Bledsoe, A. C., Durrani, S. R., Wang, C., Shaw, C., Chang, A. T., Singh, B., Kamboj, A. P., … Hirano, I. (2020). Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis. The New England Journal of Medicine, 383(17), 1624–1634. https://doi.org/10.1056/NEJMoa2012047

Dörner, T., Shock, A., & Smith, K. G. C. (2012). CD22 and autoimmune disease. International Reviews of Immunology, 31(5), 363–378. https://doi.org/10.3109/08830185.2012.709890

Duan, S., Arlian, B. M., Nycholat, C. M., Wei, Y., Tateno, H., Smith, S. A., Macauley, M. S., Zhu, Z., Bochner, B. S., & Paulson, J. C. (2021). Nanoparticles Displaying Allergen and Siglec-8 Ligands Suppress IgE-FcεRI–Mediated Anaphylaxis and Desensitize Mast Cells to Subsequent Antigen Challenge. The Journal of Immunology, 206(10), 2290–2300. https://doi.org/10.4049/jimmunol.1901212

Duan, S., Koziol-White, C. J., Jester, W. F., Smith, S. A., Nycholat, C. M., Macauley, M. S., Panettieri, R. A., & Paulson, J. C. (2019). CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen. Journal of Clinical Investigation, 129(3), 1387–1401. https://doi.org/10.1172/JCI125456

Duan, S., & Paulson, J. C. (2020). Siglecs as Immune Cell Checkpoints in Disease. Annual Review of Immunology, 38, 365–395. https://doi.org/10.1146/annurev-immunol-102419-035900

Eakin, A. J., Bustard, M. J., McGeough, C. M., Ahmed, T., Bjourson, A. J., & Gibson, D. S. (2016). Siglec-1 and -2 as potential biomarkers in autoimmune disease. Proteomics. Clinical Applications, 10(6), 635–644. https://doi.org/10.1002/prca.201500069

Edgar, L. J., Kawasaki, N., Nycholat, C. M., & Paulson, J. C. (2019). Targeted Delivery of Antigen to Activated CD169+ Macrophages Induces Bias for Expansion of CD8+ T Cells. Cell Chemcial Biology, 26(1), 131–136. https://doi.org/10.1016/j.chembiol.2018.10.006

Ehninger, A., Kramer, M., Röllig, C., Thiede, C., Bornhäuser, M., Von Bonin, M., Wermke, M., Feldmann, A., Bachmann, M., Ehninger, G., & Oelschlägel, U. (2014). Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer Journal, 4(6), e218. https://doi.org/10.1038/bcj.2014.39

Engin, A. B., Engin, E. D., & Engin, A. (2020). Dual function of sialic acid in gastrointestinal SARS-CoV-2 infection. Environmental Toxicology and Pharmacology, 79, 103436. https://doi.org/10.1016/j.etap.2020.103436

Enterina, J. R., Jung, J., & Macauley, M. S. (2019). Coordinated roles for glycans in regulating the inhibitory function of CD22 on B cells. Biomedical Journal, 42(4), 218–232. https://doi.org/10.1016/j.bj.2019.07.010

Ereño-Orbea, J., Sicard, T., Cui, H., Mazhab-Jafari, M. T., Benlekbir, S., Guarné, A., Rubinstein, J. L., & Julien, J. P. (2017). Molecular basis of human CD22 function and therapeutic targeting. Nature Communications, 8(1), 764. https://doi.org/10.1038/s41467-017-00836-6

Floyd, H., Ni, J., Cornish, A. L., Zeng, Z., Liu, D., Carter, K. C., Steel, J., & Crocker, P. R. (2000). Siglec-8. A novel eosinphil-specific member of the immunoglobulin superfamily. The Journal of Biological Chemistry, 275(2), 861–866. https://doi.org/10.1074/jbc.275.2.861

Forgione, R. E., Di Carluccio, C., Guzmán-Caldentey, J., Gaglione, R., Battista, F., Chiodo, F., Manabe, Y., Arciello, A., Del Vecchio, P., Fukase, K., Molinaro, A., Martín-Santamaría, S., Crocker, P. R., Marchetti, R., & Silipo, A. (2020). Unveiling Molecular Recognition of Sialoglycans by Human Siglec-10. IScience, 23(6), 101231. https://doi.org/10.1016/j.isci.2020.101231

Fraschilla, I., & Pillai, S. (2017). Viewing Siglecs through the lens of tumor immunology. Immunological Reviews, 276(1), 178–191. https://doi.org/10.1111/imr.12526

Freeman, S. D., Kelm, S., Barber, E. K., & Crocker, P. R. (1995). Characterization of CD33 as a new member of the Sialoadhesin family of cellular interaction molecules. Blood, 85(8), 2005–2012. https://doi.org/10.1182/blood.v85.8.2005.bloodjournal8582005

Fuster, M. M., & Esko, J. D. (2005). The sweet and sour of cancer : glycans as novel therapeutic targets. Nature Reviews Cancer, 5(7), 526–542. https://doi.org/10.1038/nrc1649

Gao, P., Shimizu, K., Grant, A. V, Rafaels, N., Zhou, L., Hudson, S. A., Konno, S., Zimmermann, N., Araujo, M. I., Ponte, E. V, Cruz, A. A., Nishimura, M., Su, S., Hizawa, N., Beaty, T. H., Mathias, R. A., Rothenberg, M. E., Barnes, K. C., & Bochner, B. S. (2010). Polymorphisms in the sialic acid-binding are associated with susceptibility to asthma. European Journal of Human Genetics, 18(6), 713–719. https://doi.org/10.1038/ejhg.2009.239

Gebremeskel, S., Schanin, J., Coyle, K. M., Butuci, M., Luu, T., Brock, E. C., Xu, A., Wong, A., Leung, J., Korver, W., Morin, R. D., Schleimer, R. P., Bochner, B. S., & Youngblood, B. A. (2021). Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation : Implications for an Anti-Siglec-8 Antibody. Frontiers in Immunology, 12, 650331. https://doi.org/10.3389/fimmu.2021.650331

Geh, D., & Gordon, C. (2018). Epratuzumab for the treatment of systemic lupus erythematosus. Expert Review of Clinical Immunology, 14(4), 245–258. https://doi.org/10.1080/1744666X.2018.1450141

Gianchecchi, E., Arena, A., & Fierabracci, A. (2021). Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments. International Journal of Molecular Sciences, 22(11), 5774. https://doi.org/10.3390/ijms22115774

Gieseke, F., Mang, P., Viebahn, S., Sonntag, I., Kruchen, A., Erbacher, A., Pfeiffer, M., Handgretinger, R., & Müller, I. (2012). Siglec-7 tetramers characterize b-cell subpopulations and leukemic blasts. European Journal of Immunology, 42(8), 2176–2186. https://doi.org/10.1002/eji.201142298

Gottenberg, J. E., Dörner, T., Bootsma, H., Devauchelle-Pensec, V Bowman, S. J., Mariette, X., Bartz, H., Oortgiesen, M., Shock, A., Koetse, W., Galateanu, C., Bongardt, S., Wegener, W. A., Goldenberg, D. M., Meno-Tetang, G., Kosutic, G., & Gordon, C. (2018). Efficacy of epratuzumab, an anti-CD22 monoclonal IgG antibody, in systemic lupus erythematosus patients with associated sjogren’s syndrome : post hoc analyses from the EMBODY trials. Arthritis Rheum., 70(5), 763–773. https://doi.org/10.1002/art.40425

Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013). Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron, 78(4), 631–643. https://doi.org/10.1016/j.neuron.2013.04.014

Gummuluru, S., Pina Ramirez, N. G., & Akiyama, H. (2014). CD169-dependent cell-associated HIV-1 transmission : a driver of virus dissemination. Journal of Infectious Diseases, 210((Suppl 3)), S641–S647. https://doi.org/10.1093/infdis/jiu442

Haas, Q., Boligan, K. F., Jandus, C., Schneider, C., Simillion, C., Stanczak, M. A., Haubitz, M., Jafari, S. M. S., Zippelius, A., Baerlocher, G. M., Laubli, H., Hunger, R. E., Romero, P., Simon, H.-U., & von Gunten, S. (2019). Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment. Cancer Immunology Research, 7(5), 707–718. https://doi.org/10.1158/2326-6066.CIR-18-0505

Hartnell, A., Steel, J., Turley, H., Jones, M., Jackson, D. G., & Crocker, P. R. (2001). Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflam- matory macrophage populations. Blood, 97(1), 288–296. https://doi.org/10.1182/blood.v97.1.288

Heida, R., Bhide, Y. C., Gasbarri, M., Kocabiyik, Ö., Stellacci, F., Huckriede, A. L. W., Hinrichs, W. L. J., & Frijlink, H. W. (2021). Advances in the development of entry inhibitors for sialic-acid-targeting viruses. Drug Discovery Today, 26(1), 122–137. https://doi.org/10.1016/j.drudis.2020.10.009

Hudak, J. E., Canham, S. M., & Bertozzi, C. R. (2014). Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nature Chemical Biology, 10(1), 69–75. https://doi.org/10.1038/nchembio.1388

Jandus, C., Boligan, K. F., Chijioke, O., Liu, H., Dahlhaus, M., Démoulins, T., Schneider, C., Wehrli, M., Hunger, R. E., Baerlocher, G. M., Simon, H. U., Romero, P., Münz, C., & Von Gunten, S. (2014). Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. Journal of Clinical Investigation, 124(4), 1810–1820. https://doi.org/10.1172/JCI65899

Jandus, C., Simon, H., & Gunten, S. Von. (2011). Targeting Siglecs — A novel pharmacological strategy for immuno- and glycotherapy. Biochemical Pharmacology, 82(4), 323–332. https://doi.org/10.1016/j.bcp.2011.05.018

Jia, Y., Yu, H., Fernandes, S. M., Wei, Y., Gonzalez-gil, A., Bochner, B. S., Kern, R. C., Schleimer, R. P., & Schnaar, R. L. (2015). Expression of ligands for Siglec-8 and Siglec-9 in human airways and airway cells. Journal of Allergy and Clinical Immunology, 135(3), 799–810. https://doi.org/10.1016/j.jaci.2015.01.004

Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O’Brien, S., Wang, K., Wang, T., Paccagnella, M. L., Sleight, B., Vandendries, E., & Advani, A. S. (2016). Inotuzumab ozogamicin versus standard therapy for acute lym-phoblastic leukemia. The New England Journal of Medicine, 375(8), 740–753. https://doi.org/10.1056/NEJMoa1509277

Kelm, S, Brossmer, R., Isecke, R., Gross, H. J., Strenge, K., & Schauer, R. (1998). Functional groups of sialic acids involved in binding to siglecs (sialoadhesins) deduced from interactions with synthetic analogues. European Journal of Biochemistry, 255(3), 663–672. https://doi.org/10.1046/j.1432-1327.1998.2550663.x.

Kelm, S., Gerlach, J., Brossmer, R., Danzer, C., & Nitschke, L. (2002). The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound. Journal of Experimental Medicine, 195(9), 1207–1213. https://doi.org/10.1084/jem.20011783

Kelm, S., Madge, P., Islam, T., Bennett, R., Koliwer-Brandl, H., Waespy, M., Von Itzstein, M., & Haselhorst, T. (2013). C-4 modified sialosides enhance binding to Siglec-2 (CD22) : Towards potent Siglec inhibitors for immunoglycotherapy. Angewandte Chemie - International Edition, 52(13), 3616–3620. https://doi.org/10.1002/anie.201207267

Kelm, S., Pelz, A., Schauer, R., Filbin, M. T., Tang, S., Bellard, M.-E. de, Schnaar, R. L., Mahoney, J. A., Hartnell, A., Bradfield, P., & Crocker, P. R. (1994). Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family of sialic acid-dependent adhesion molecules of the immu- noglobulin superfamily. Current Biology, 4(11), 965–972. https://doi.org/10.1016/s0960-9822(00)00220-7

Kikly, K. K., Bochner, B. S., Freeman, S. D., Tan, K. B., Gallagher, K. T., D’alessio, K. J., Holmes, S. D., Abrahamson, J. A., Erickson-Miller, C L Murdock, P. R., Tachimoto, H., Schleimer, R. P., & White, J. R. (2000). Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils. Journal of Allergy and Clinical Immunology, 105(6 (Pt 1)), 1093–1100. https://doi.org/10.1067/mai.2000.107127

Kimura, N., Ohmori, K., Miyazaki, K., Izawa, M., Matsuzaki, Y., Yasuda, Y., Takematsu, H., Kozutsumi, Y., Moriyama, A., & Kannagi, R. (2007). Human B-lymphocytes express alpha2-6-sialylated 6-sulfo-N-acetyllactosamine serving as a preferred ligand for CD22/Siglec-2. The Journal of Biological Chemistry, 282(44), 32200–32207. https://doi.org/10.1074/jbc.M702341200

Klaas, M., Oetke, C., Lewis, L. E., Lars, P., Heikema, A. P., Easton, A., Willison, H. J., & Crocker, P. R. (2012). Sialoadhesin Promotes Rapid Proinflammatory and Type I IFN Responses to a Sialylated Pathogen, Campylobacter jejuni. The Journal of Immunology, 189(5), 2414–2422. https://doi.org/10.4049/jimmunol.1200776

Kovalovsky, D., Yoon, J. H., Cyr, M. G., Simon, S., Voynova, E., Rader, C., Wiestner, A., Alejo, J., Pittaluga, S., & Gress, R. E. (2021). Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia. Leukemia, 35(9), 2581–2591. https://doi.org/10.1038/s41375-021-01188-3

Kroezen, B. S., Conti, G., Girardi, B., Cramer, J., Jiang, X., Rabbani, S., Müller, J., Kokot, M., Luisoni, E., Ricklin, D., Schwardt, O., & Ernst, B. (2020). A Potent Mimetic of the Siglec-8 Ligand 6’-Sulfo-Sialyl Lewisx. ChemMedChem, 15(18), 1706–1719. https://doi.org/10.1002/cmdc.202000417

Lai, C., Brow, M. A., Nave, K. A., Noronha, A. B., Quarles, R. H., Bloom, F. E., Milner, R. J., & Sutcliffe, J. G. (1987). Two forms of 1B236/myelin-associated glycoprotein, a cell adhesion molecule for postnatal neural development, are produced by alternative splicing. Proc. Natl. Acad. Sci. USA, 84(12), 4337–4341. https://doi.org/10.1073/pnas.84.12.4337

Landolina, N., Zaffran, I., Smiljkovic, D., Serrano-Candelas, E., Schmiedel, D., Friedman, S., Arock, M., Hartmann, K., Pikarsky, E., Mandelboim, O., Martin, M., Valent, P., & Levi-Schaffer, F. (2020). Activation of Siglec-7 results in inhibition of in vitro and in vivo growth of human mast cell leukemia cells. Pharmacological Research, 158, 104682. https://doi.org/10.1016/j.phrs.2020.104682

Läubli, H., Kawanishi, K., George Vazhappilly, C., Matar, R., Merheb, M., & Siddiqui, S. S. (2020). Tools to study and target the Siglec-sialic acid axis in cancer. The FEBS Journal, 288(21), 6206–6225. https://doi.org/10.1111/febs.15647

Läubli, H., & Varki, A. (2020). Sialic acid–binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses. Cellular and Molecular Life Sciences, 77(4), 593–605. https://doi.org/10.1007/s00018-019-03288-x

Legrand, F., Landolina, N., Zaffran, I., Emeh, R. O., Chen, E., Klion, A. D., & Levi-Schaffer, F. (2019). Siglec-7 on peripheral blood eosinophils : surface expression and function. Allergy : European Journal of Allergy and Clinical Immunology, 74(7), 1257–1265. https://doi.org/10.1111/all.13730

Lenza, M. P., Atxabal, U., Oyenarte, I., Jiménez-Barbero, J., & Ereño-Orbea, J. (2020). Current Status on Therapeutic Molecules Targeting Siglec Receptors. Cells, 9(12), 2691. https://doi.org/10.3390/cells9122691

Leonard, J. P., & Goldenbergm, D. M. (2007). Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene, 26(25), 3704–3713. https://doi.org/10.1038/sj.onc.1210370

Levine, H. T., Tauber, J., Nguyen, Q., & Anesi, S. D. (2020). Phase 1b Study of AK002, an Anti-Siglec-8 (1) Levine, H. T. ; Tauber, J. ; Nguyen, Q. ; Anesi, S. D. Phase 1b Study of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Patients with Severe Allergic Conjunctivitis (KRONOS Study). Journal of Allergy and Clinical Immunology, 145(2), AB185. https://doi.org/10.1016/j.jaci.2019.12.323

Li, N., Zhang, W., Wan, T., Zhang, J., Chen, T., Yu, Y., Wang, J., & Cao, X. (2001). Clo ning and Characterization of Siglec-10, a Novel Sialic Acid Binding Member of the Ig Superfamily, from Human Dendritic Cells. Journal of Biological Chemistry, 276(30), 28106–28112. https://doi.org/10.1074/jbc.M100467200

Linnartz, B., Wang, Y., & Neumann, H. (2010). Microglial immunoreceptor tyrosine-based activation and inhibition motif signaling in neuroinflammation. International Journal of Alzheimer’s Disease, 2010, 587463. https://doi.org/10.4061/2010/587463.

Lock, K., Zhang, J., Lu, J., Lee, S. H., & Crocker, P. R. (2004). Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells. Immunobiology, 209(1–2), 199–207. https://doi.org/10.1016/j.imbio.2004.04.007

Lopez, P. H. H. (2014). Role of myelin-associated glycoprotein (siglec-4a) in the nervous system. Advances in Neurobiology, 9, 245–262. https://doi.org/10.1007/978-1-4939-1154-7_11

Maakaron, J. E., Rogosheske, J., Long, M., Bachanova, V., & Mims, A. S. (2021). CD33-Targeted Therapies : Beating the Disease or Beaten to Death ? Journal of Clinical Pharmacology, 61(1), 7–17. https://doi.org/10.1002/jcph.1730

Macauley, M. S., Crocker, P. R., & Paulson, J. C. (2014). Siglec-mediated regulation of immune cell function in disease. Nature Reviews Immunology, 14(10), 653–666. https://doi.org/10.1038/nri3737

Macauley, M. S., Kawasaki, N., Peng, W., Wang, S. H., He, Y., Arlian, B. M., McBride, R., Kannagi, R., Khoo, K. H., & Paulson, J. C. (2015). Unmasking of CD22 co-receptor on germinal center B-cells occurs by alternative mechanisms in mouse and man. Journal of Biological Chemistry, 290(50), 30066–30077. https://doi.org/10.1074/jbc.M115.691337

Macauley, M. S., & Paulson, J. C. (2014). Immunology : glyco-engineering “super-self.” Nature Chemical Biology, 10(1), 7–8. https://doi.org/10.1038/nchembio.1415

Macauley, M. S., Pfrengle, F., Rademacher, C., Nycholat, C. M., Gale, A. J., Von Drygalski, A., & Paulson, J. C. (2013). Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis. Journal of Clinical Investigation, 123(7), 3074–3083. https://doi.org/10.1172/JCI69187

Maggi, E., & Moretta, L. (2020). Siglec-7, a target for novel therapeutical approaches of Systemic Mastocytosis. Pharmacological Research, 158, 104731. https://doi.org/10.1016/j.phrs.2020.104731

Matsubara, N., Imamura, A., Yonemizu, T., Akatsu, C., Yang, H., Ueki, A., Watanabe, N., Abdu-Allah, A., Numoto, N., Takematsu, H., Kitazume, S., Tedder, T. F., Marth, J. D., Ito, N., Ando, H., Ishida, H., Kiso, M., & Tsubata, T. (2018). CD22- Binding synthetic sialosides regulate B lymphocyte proliferation through CD22 ligand-dependent and independent pathways, and enhance antibody production in mice. Frontiers in Immunology, 9, 820. https://doi.org/10.3389/fimmu.2018.00820

May, A. P., Robinson, R. C., Vinson, M., Crocker, P. R., & Jones, E. Y. (1998). Crystal structure of the N-terminal domain of sialoadhesin in complex with 3′ sialyllactose at 1.85 A resolution. Molecular Cell, 1(5), 719–728. https://doi.org/10.1016/S1097-2765(00)80071-4

McDonald, D., Wu, L., Bohks, S. M., KewalRamani, V. N., Unutmaz, D., & Hope, T. J. (2003). Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science, 300(5623), 1295–1297. https://doi.org/10.1126/science.1084238

McKerracher, L., & Rosen, K. M. (2015). MAG, myelin and overcoming growth inhibition in the CNS. Frontiers in Molecular Neuroscience, 8, 51. https://doi.org/10.3389/fnmol.2015.00051

Mesch, S., Moser, D., Strasser, D. S., Kelm, A., Cutting, B., Rossato, G., Vedani, A., Koliwer-Brandl, H., Wittwer, M., Rabbani, S., Schwardt, O., Kelm, S., & Ernst, B. (2010). Low molecular weight antagonists of the myelin-associated glycoprotein : synthesis, docking, and biological evaluation. Journal of Medicinal Chemistry, 53(4), 1597–1615. https://doi.org/10.1021/jm901517k

Miles, L. A., Hermans, S. J., Gabriela, A. N., Nancy, N. C., Parker, W., Miles, L. A., Hermans, S. J., Crespi, G. A. N., Gooi, J. H., Doughty, L., Nero, T. L., Markuli, J., Ebneth, A., Wroblowski, B., Oehlrich, D., Trabanco, A. A., Rives, M. L., Royaux, I., N, H., & Parker, M. W. (2019). Small Molecule Binding to Alzheimer Risk Factor CD33 Promotes Aβ Phagocytosis. IScience, 19, 110–118. https://doi.org/10.1016/j.isci.2019.07.023

Movsisyan, L. D., & Macauley, M. S. (2020). Structural advances of Siglecs  : insight into synthetic glycan ligands for immunomodulation. Organic & Biomolecular Chemistry, 18(30), 5784–5797. https://doi.org/10.1039/d0ob01116a

Munday, J., Floyd, H., & Crocker, P. R. (1999). Sialic acid binding receptors (siglecs) expressed by macrophages. Journal of Leukocyte Biology, 66(5), 705–711. https://doi.org/10.1002/jlb.66.5.705

Nakamura, K., Yamaji, T., Crocker, P. R., Suzuki, A., & Hashimoto, Y. (2002). Lymph node macrophages, but not spleen macrophages, express high levels of unmasked sialoadhesin : implication for the adhesive properties of macrophages in vivo. Glycobiology, 12(3), 209–216. https://doi.org/10.1093/glycob/12.3.209

Nguyen, K. A., Hamzeh-Cognasse, H., Palle, S., Anselme-Bertrand, I., Arthaud, C. A., Chavarin, P., Pozzetto, B., Garraud, O., & Cognasse, F. (2014). Role of siglec-7 in apoptosis in human platelets. PLoS ONE, 9(9), e106239. https://doi.org/10.1371/journal.pone.0106239

Nicoll, G., Avril, T., Lock, K., Furukawa, K., Bovin, N., & Crocker, P. R. (2003). Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms. European Journal of Immunology, 33(6), 1642–1648. https://doi.org/10.1002/eji.200323693

Nitschke, L. (2005). The role of CD22 and other inhibitory co-receptors in B-cell activation. Current Opinion in Immunology, 17(3), 290–297. https://doi.org/10.1016/j.coi.2005.03.005

Nutku-bilir, E., Hudson, S. A., & Bochner, B. S. (2008). Interleukin-5 priming of human eosinophils alters Siglec-8 – mediated apoptosis pathways. American Journal of Respiratory Cell and Molecular Biology, 38(1), 121–124. https://doi.org/10.1165/rcmb.2007-0154OC

Nutku, E., Aizawa, H., Hudson, S. A., & Bochner, B. S. (2003). Ligation of Siglec-8  : a selective mechanism for induction of human eosinophil apoptosis. Blood, 101(12), 5014–5020. https://doi.org/10.1182/blood-2002-10-3058

Nycholat, C. M., Duan, S., Knuplez, E., Worth, C., Elich, M., Yao, A., O’Sullivan, J., McBride, R., Wei, Y., Fernandes, S. M., Zhu, Z., Schnaar, R. L., Bochner, B. S., & Paulson, J. C. (2019). A Sulfonamide Sialoside Analogue for Targeting Siglec-8 and-F on Immune Cells [Rapid-communication]. Journal of the American Chemical Society, 141(36), 14032–14037. https://doi.org/10.1021/jacs.9b05769

Nycholat, C. M., Rademacher, C., Kawasaki, N., & Paulson, J. C. (2012). In Silico-Aided Design of a Glycan Ligand of Sialoadhesin for in Vivo Targeting of Macrophages. Journal of the American Chemical Society, 134(38), 15696–15699. https://doi.org/10.1021/ja307501e

O’Neill, A. S. G., Van Den Berg, T. K., & Mullen, G. E. D. (2013). Sialoadhesin - a macrophage-restricted marker of immunoregulation and inflammation. Immunology, 138(3), 198–207. https://doi.org/10.1111/imm.12042

O’Reilly, M. K., Tian, H., & Paulson, J. C. (2011). CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells. Journal of Immunology, 186(3), 1554–1563. https://doi.org/10.4049/jimmunol.1003005

O’Sullivan, J. A., Carroll, D. J., Cao, Y., Salicru, A. N., & Bochner, B. S. (2018). Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells. Journal of Allergy and Clinical Immunology, 141(5), 1774-1785.e7. https://doi.org/10.1016/j.jaci.2017.06.028

Orr, S. J., Morgan, N. M., Elliott, J., Burrows, J. F., Scott, C. J., McVicar, D. W., & Johnston, J. A. (2007). CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. Blood, 109(3), 1061–1068. https://doi.org/10.1182/blood-2006-05-023556

Patel, N., Brinkman-Van Der Linden, E. C. M., Altmann, S. W., Gish, K., Balasubramanian, S., Timans, J. C., Peterson, D., Bell, M. P., Bazan, J. F., Varki, A., & Kastelein, R. A. (1999). OB-BP1/Siglec-6. A leptin- and sialic acid-binding protein of the immunoglobulin superfamily. Journal of Biological Chemistry, 274(32), 22729–22738. https://doi.org/10.1074/jbc.274.32.22729

Paul, S. P., Taylor, L. S., Stansbury, E. K., & McVicar, D. W. (2000). Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood, 96(2), 483–490. https://doi.org/10.1182/blood.v96.2.483

Peng, W., & Paulson, J. C. (2017). CD22 Ligands on a Natural N-Glycan Scaffold Efficiently Deliver Toxins to B-Lymphoma Cells. Journal of the American Chemical Society, 139(36), 12450–12458. https://doi.org/10.1021/jacs.7b03208

Pérez-Oliva, A. B., Martínez-Esparza, M., Vicente-Fernández, J. J., Corral-San Miguel, R., García-Peñarrubia, P., & Hernández-Caselles, T. (2011). Epitope mapping, expression and post-translational modifications of two isoforms of CD33 (CD33M and CD33m) on lymphoid and myeloid human cells. Glycobiology, 21(6), 757–770. https://doi.org/10.1093/glycob/cwq220

Perez-Zsolt, D., Erkizia, I., Pino, M., García-Gallo, M., Martin, M., Benet, S., Chojnacki, J., Fernández-Figueras, M. T., Guerrero, D., Urrea, V., Muñiz-Trabudua, X., Kremer, L., Martinez-Picado, J., & Izquierdo-Useros, N. (2019). Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry. Nature Microbiology, 4(9), 1558–1570. https://doi.org/10.1038/s41564-019-0453-2

Perez-zsolt, D., Martinez-Picado, J., & Izquierdo-Useros, N. (2019). When Dendritic Cells Go Viral  : The Role of Siglec-1 in Host Defense and Dissemination of Enveloped Viruses. Viruses, 12(1), 8. https://doi.org/10.3390/v12010008

Pillai, S., Netravali, I. A., Cariappa, A., & Mattoo, H. (2012). Siglecs and Immune Regulation. Annual Reviews, 30, 357–392. https://doi.org/10.1146/annurev-immunol-020711-075018

Poe, J. C., Fujimoto, Y., Hasegawa, M., Haas, K. M., Miller, A. S., Sanford, I. G., Bock, C. B., Fujimoto, M., & Tedder, T. F. (2004). CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nature Immunology, 5(10), 1078–1087. https://doi.org/10.1038/ni1121

Prescher, H., Frank, M., Gütgemann, S., Kuhfeldt, E., Schweizer, A., Nitschke, L., Watzl, C., & Brossmer, R. (2017). Design, Synthesis, and Biological Evaluation of Small, High-Affinity Siglec-7 Ligands : Toward Novel Inhibitors of Cancer Immune Evasion. Journal of Medicinal Chemistry, 60(3), 941–956. https://doi.org/10.1021/acs.jmedchem.6b01111

Prescher, H., Schweizer, A., Kuhfeldt, E., Nitschke, L., & Brossmer, R. (2014). Discovery of Multifold Modified Sialosides as Human CD22/Siglec 2 Ligands with Nanomolar Activity on B Cells. ACS Chemical Biology, 9(7), 1444–1450. https://doi.org/10.1021/cb400952v

Pronker, M. F., Lemstra, S., Snijder, J., Heck, A. J. R., Thies-Weesie, D. M. E., Pasterkamp, R. J., & Janssen, B. J. C. (2016). Structural basis of myelin-associated glycoprotein adhesion and signalling. Nature Communications, 7, 13584. https://doi.org/10.1038/ncomms13584

Pröpster, J. M., Yang, F., Rabbani, S., Ernst, B., Allain, F. H., & Schubert, M. (2016). Structural basis for sulfation-dependent self-glycan recognition by the human immune-inhibitory receptor Siglec-8. Proc. Natl. Acad. Sci., 113(29), E4170–E4179. https://doi.org/10.1073/pnas.1602214113

Quarles, R. H. (2007). Myelin-associated glycoprotein (MAG) : past, present and beyond. Journal of Neurochemistry, 100(6), 1431–1438. https://doi.org/10.1111/j.1471-4159.2006.04319.x.

Rillahan, C.D., Schwartz, E., McBride, R., Fokin, V. V, & Paulson, J. C. (2012). Click and pick : identification of sialoside analogues for siglec-based cell targeting. Angewandte Chemie - International Ed. in English, 51(44), 11014–11018. https://doi.org/10.1002/anie.201205831

Rillahan, C.D., Schwartz, E., Rademacher, C., McBride, R., Rangarajan, J., Fokin, V. V., & Paulson, J. C. (2013). On-chip synthesis and screening of a sialoside library yields a high affinity ligand for Siglec-7. ACS Chemical Biology, 8(7), 1417–1422. https://doi.org/10.1021/cb400125w

Rillahan, C.D., Macauley, M. S., Schwartz, E., He, Y., Arlian, B. M., Rangarajan, J., Fokin, V. V, & Paulson, J. C. (2014). Disubstituted Sialic Acid Ligands Targeting Siglecs CD33 and CD22 Associated with Myeloid Leukaemias and B Cell Lymphomas. Chemical Science, 5(6), 2398–2406. https://doi.org/10.1039/C4SC00451E.

Robertson, M. J., Soiffer, R. J., Freedman, A. S., Rabinowe, S. L., Anderson, K. C., Ervin, T. J., Murray, C., Dear, K., Griffin, J. D., Nadler, L. M., & Ritz, J. (1992). Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis : Clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood, 79(9), 2229–2236. https://doi.org/10.1182/blood.v79.9.2229.2229

Rumer, K. K., Uyenishi, J., Hoffman, M. C., Fisher, B. M., & Winn, V. D. (2013). Siglec-6 expression is increased in placentas from pregnancies complicated by preterm preeclampsia. Reproductive Sciences, 20(6), 646–653. https://doi.org/10.1177/1933719112461185

Schanin, J., Gebremeskel, S., Korver, W., Falahati, R., Butuci, M., Haw, T. J., Nair, P. M., Liu, G., Hansbro, N. G., Hansbro, P. M., Evensen, E., Brock, E. C., Xu, A., Wong, A., Leung, J., Bebbington, C., Tomasevic, N., & Youngblood, B. A. (2021). A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation. Mucosal Immunology, 14(2), 366–376. https://doi.org/10.1038/s41385-020-00336-9

Schauer, R., & Kamerling, J. P. (2018). Exploration of the Sialic Acid World. Advances in Carbohydrate Chemistry and Biochemistry, 75, 1–213. https://doi.org/10.1016/bs.accb.2018.09.001

Schwardt, O., Kelm, S., & Ernst, B. (2015). SIGLEC-4 (MAG) Antagonists : From the Natural Carbohydrate Epitope to Glycomimetics. Topics in Current Chemistry, 367, 151–200. https://doi.org/10.1007/128_2013_498

Schweizer, A., Wöhner, M., Prescher, H., Brossmer, R., & Nitschke, L. (2012). Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues. European Journal of Immunology, 42(10), 2792–2802.

Sewald, X., Ladinsky, M. S., Uchil, P. D., Beloor, J., Pi, R., Herrmann, C., Motamedi, N., Murooka, T. T., Brehm, M. A., Greiner, D. L., Shultz, L. D., Mempel, T. R., Bjorkman, P. J., Kumar, P., & Mothes, W. (2015). Retroviruses use CD169-mediated trans-infection of permissive lymphocytes to establish infection. Science, 350(6260), 563–567. https://doi.org/10.1126/science.aab2749

Shahraz, A., Kopatz, J., Mathy, R., Kappler, J., Winter, D., Kapoor, S., Schütza, V., Scheper, T., Gieselmann, V., & Neumann, H. (2015). Anti-inflammatory activity of low molecular weight polysialic acid on human macrophages. Scientific Reports, 5, 16800. https://doi.org/10.1038/srep16800

Shao, J. Y., Yin, W. W., Zhang, Q. F., Liu, Q., Peng, M. L., Hu, H. D., Hu, P., Ren, H., & Zhang, D. Z. (2016). Siglec-7 Defines a Highly Functional Natural Killer Cell Subset and Inhibits Cell-Mediated Activities. Scandinavian Journal of Immunology, 84(3), 182–190. https://doi.org/10.1111/sji.12455

Sheikh, A. A. ., Akatsu, C., Imamura, A., Abdu-Allah, H. H. M., Takematsu, H., Ando, H., Ishida, H., Kiso, M., & Tsubata, T. (2018). Proximity labeling of cis-ligands of CD22/Siglec-2 reveals stepwise alpha2,6 sialic acid-dependent and -independent interactions, Biochem. Biophys. Res. Commun. Biochemical and Biophysical Research Communications, 495(1), 854–859. https://doi.org/10.1016/j.bbrc.2017.11.086

Shelke, S. V., Cutting, B., Jiang, X., Koliwer-Brandl, H., Strasser, D. S., Schwardt, O., Kelm, S., & Ernst, B. (2010). A fragment-based in situ combinatorial approach to identify high-affinity ligands for unknown binding sites. Angewandte Chemie - International Edition, 49(33), 5721–5725. https://doi.org/10.1002/anie.200907254

Shelke, S. V, Gao, G., Mesch, S., Gathje, H., Kelm, S., Schwardt, O., & Ernst, B. (2007). Synthesis of sialic acid derivatives as ligands for the myelin-associated glycoprotein (MAG). Bioorganic & Medicinal Chemistry, 15(14), 4951–4965. https://doi.org/10.1016/j.bmc.2007.04.038

Siddiqui, S. S., Matar, R., Merheb, M., Hodeify, R., Vazhappilly, C. G., Marton, J., Shamsuddin, S. A., & Al Zouabi, H. (2019). Siglecs in Brain Function and Neurological Disorders. Cells, 8(10), 1125. https://doi.org/10.3390/cells8101125

Siebenhaar, F., Bonnekoh, H., Hawro, T., Hawro, M., Michaelis, E., Rasmussen, H., Singh, B., Kantor, A., Chang, A., & Maurer, M. (2019). Safety and efficacy data of AK002, an anti-Siglec-8 monoclonal antibody, in patients with indolent systemic mastocytosis (ISM) : Results from a first-in-human, open-label phase 1 study. Allergy, 74, 854–915.

Stanczak, M. A., Siddiqui, S. S., Trefny, M. P., Thommen, D. S., Boligan, K. F., Von Gunten, S., Tzankov, A., Tietze, L., Lardinois, D., Heinzelmann-Schwarz, V., Von Bergwelt-Baildon, M., Zhang, W., Lenz, H. J., Han, Y., Amos, C. I., Syedbasha, M., Egli, A., Stenner, F., Speiser, D. E., Läubli, H. (2018). Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. Journal of Clinical Investigation, 128(11), 4912–4923. https://doi.org/10.1172/JCI120612

Sullivan-Chang, L., O’Donnell, R. T., & Tuscano, J. M. (2013a). Targeting CD22 in B-cell malignancies : Current status and clinical outlook. BioDrugs, 27(4), 293–304. https://doi.org/10.1007/s40259-013-0016-7

Sullivan-Chang, L., O’Donnell, R. T., & Tuscano, J. M. (2013b). Targeting CD22 in B-cell malignancies : Current status and clinical outlook. BioDrugs, 27, 293–304. https://doi.org/10.1007/s40259-013-0016-7

Takamiya, R., Ohtsubo, K., Takamatsu, S., Taniguchi, N., & Angata, T. (2013). The interaction between Siglec- 15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway. Glycobiology, 23(2), 178–187. https://doi.org/10.1093/glycob/cws139

Tedder, T. F., Poe, J. C., & Haas, K. M. (2005). CD22 : A multifunctional receptor that regulates B lymphocyte survival and signal transduction. Advances in Immunology, 88, 1–50. https://doi.org/10.1016/S0065-2776(05)88001-0

Tsubata, T. (2012). Role of inhibitory BCR co-receptors in immunity. 2012 ;12(3):181–190. Infectious Disorders Drug Targets, 12(3), 181–190. https://doi.org/10.2174/187152612800564455

Tsuda, E., Fukuda, C., Okada, A., Karibe, T., Hiruma, Y., Takagi, N., Isumi, Y., Yamamoto, T., Hasegawa, T., Uehara, S., Koide, M., Udagawa, N., Amizuka, N., & Kumakura, S. (2022). Characterization, pharmacokinetics, and pharmacodynamics of anti-Siglec-15 antibody and its potency for treating osteoporosis and as follow-up treatment after parathyroid hormone use. Bone, 155, 116241. https://doi.org/10.1016/j.bone.2021.116241

Van Der Merwe, P. A., Crocker, P. R., Vinson, M., Barclay, A. N., Schauer, R., & Kelm, S. (1996). Localization of the putative sialic acid-binding site on the immunoglobulin superfamily cell-surface molecule CD22. Journal of Biological Chemistry, 271(16), 9273–9280. https://doi.org/10.1074/jbc.271.16.9273

Varki, A. (2001). Loss of N-glycolylneuraminic acid in humans : mechanisms, consequences, and implications for hominid evolution. American Journal of Physical Anthropology, Suppl 3, 54–69. https://doi.org/10.1002/ajpa.10018.abs

Varki, A,. Cummings, R. D., Aebi, M., Parker, N. H., Seeberger, P. H., Esko, J. D., Stanley, P., Hart, G., Darvill, A., Kinoshita, T., Prestegard, J. J., Schnaar, R. L., Freeze, H. H., Marta, J. D., Bertozzi, C. R., Etzler, M. E., Frank, M., Vligenthart, J. F. G., Lutteke, T., Korfeld, S. (2016). Symbol Nomenclature for Graphical Representation of Glycans. Glycobiology, 25(12), 1323–1324. https://doi.org/10.1093/glycob/cwv091

Varki, A., Schnaar, R. L., & Crocker, P. R. (2015). I-Type Lectins. In Essentials of Glycobiology (pp. 453–467).

Varki, A. (2008). Sialic acids in human health and disease. Trends in Molecular Medicine, 14(8), 351–360. https://doi.org/10.1016/j.molmed.2008.06.002

Varki, A. & Angata, T. (2006). Siglecs — the major subfamily of I-type lectins. Glycobiology, 16(1), 1R-27R. https://doi.org/10.1093/glycob/cwj008

von Gunten, S., & Bochner, B. S. (2008). Basic and Clinical Immunology of Siglecs. Annals of the New York Academy of Sciences, 1143, 61–82. https://doi.org/10.1196/annals.1443.011

von Gunten, S., Vogel, M., Schaub, A., Stadler, B. M., Miescher, S., Crocker, P. R., & Simon, H. (2007). Intravenous immunoglobulin preparations contain anti – Siglec-8 autoantibodies. Journal of Allergy and Clinical Immunology, 119(4), 1005–1011. https://doi.org/10.1016/j.jaci.2007.01.023

Von Gunten, S., Yousefi, S., Seitz, M., Jakob, S. M., Schaffner, T., Seger, R., Takala, J., Villiger, P. M., & Simon, H.-U. (2005). Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment. Blood, 106(4), 1423–1431. https://doi.org/10.1182/blood-2004-10-4112

Walter, R. B., Raden, B. W., Zeng, R., Häusermann, P., Bernstein, I. D., & Cooper, J. A. (2008). ITIM-dependent endocytosis of CD33-related Siglecs : role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2. Journal of Leukocyte Biology, 83(1), 200–211. https://doi.org/10.1189/jlb.0607388

Wang, B. (2012). Molecular mechanism underlying sialic acid as an essential nutrient for brain development and cognition. Advances in Nutrition, 3(3), 465S-72S. https://doi.org/10.3945/an.112.001875.

Wang, J., Sun, J., Liu, L. N., Flies, D. B., Nie, X., Toki, M., Zhang, J., Song, C., Zarr, M., Zhou, X., Han, X., Archer, K. A., O’Neill, T., Herbst, R. S., Boto, A. N., Sanmamed, M. F., Langermann, S., Rimm, D. L., & Chen, L. (2019). Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nature Medicine, 25(4), 656–666. https://doi.org/10.1038/s41591-019-0374-x

Wang, X., Mitra, N., Cruz, P., Deng, L., Varki, N., Angata, T., Green, E. D., Mullikin, J., Hayakawa, T., & Varki, A. (2012). Evolution of siglec-11 and siglec-16 genes in hominins. Molecular Biology and Evolution, 29(8), 2073–2086. https://doi.org/10.1093/molbev/mss077

Wang, Y., & Neumann, H. (2010). Alleviation of neurotoxicity by microglial human Siglec-11. Journal of Neuroscience, 30(9), 3482–3488. https://doi.org/10.1523/JNEUROSCI.3940-09.2010

Winterstein, C., Trotter, J., & Krämer-Albers, E. M. (2008). Distinct endocytic recycling of myelin proteins promotes oligodendroglial membrane remodeling. Journal of Cell Science, 121(Pt 6), 834–842. https://doi.org/10.1242/jcs.022731

Xiong, Y. S., Cheng, Y., Lin, Q. S., Wu, A. L., Yu, J., Li, C., Sun, Y., Zhong, R. Q., & Wu, L. J. (2014). Increased expression of Siglec-1 on peripheral blood monocytes and its role in mononuclear cell reactivity to autoantigen in rheumatoid arthritis. Rheumatology (Oxford)., 53(2), 250–259. https://doi.org/10.1093/rheumatology/ket342

Yamakawa, N., Yasuda, Y., Yoshimura, A., Goshima, A., Crocker, P. R., Vergoten, G., Nishiura, Y., Takahashi, T., Hanashima, S., Matsumoto, K., Yamaguchi, Y., Tanaka, H., Kitajima, K., & Sato, C. (2020). Discovery of a new sialic acid binding region that regulates Siglec-7. Scientific Reports, 10(1), 8647. https://doi.org/10.1038/s41598-020-64887-4

Yamauchi, J., Miyamoto, Y., Torii, T., Takashima, S., Kondo, K., Kawahara, K., Nemoto, N., Chan, J. R., Tsujimoto, G., & Tanoue, A. (2012). Phosphorylation of cytohesin-1 by Fyn is required for initiation of myelination and the extent of myelination during development. Science Signaling, 5(243), ra69. https://doi.org/10.1126/scisignal.2002802

Yokoi, H., Choi, O. H., Hubbard, W., Lee, H., Canning, B. J., Lee, H. H., Ryu, S., Gunten, S. Von, Bickel, C. A., Hudson, S. A., Macglashan, D. W., & Bochner, B. S. (2008). Inhibition of FcεRI-dependent mediator release and calcium flux from human mast cells by sialic acid – binding immunoglobulin-like lectin 8 engagement. Journal of Allergy and Clinical Immunology, 121(2), 499–506. https://doi.org/10.1016/j.jaci.2007.10.004

York, M. R., Nagai, T., Mangini, A. J., Lemaire, R., van Seventer, J. M., & Lafyatis, R. (2007). A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis and Rheumatism, 56(3), 1010–1020. https://doi.org/10.1002/art.22382

Yu, H. F., Gonzalez-Gil, A., Wei, Y. D., Fernandes, S. M., Porell, R. N., Vajn, K., Paulson, J. C., Nycholat, C. M., & Schnaar, R. L. (2017). Siglec-8 and Siglec-9 binding specificities and endogenous airway ligand distributions and properties. Glycobiology, 27(7), 657–668. https://doi.org/10.1093/glycob/cwx026

Zaccai, N. R., Maenaka, K., Maenaka, T., Crocker, P. R., Brossmer, R., Kelm, S., & Jones, E. Y. (2003). Structure-guided design of sialic acid-based Siglec inhibitors and crystallographic analysis in complex with sialoadhesin. Structure, 11(5), 557–567. https://doi.org/10.1016/S0969-2126(03)00073-X

Zhang, J. Q., Nicoll, G., Jones, C., & Crocker, P. R. (2000). Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes. The Journal of Biological Chemistry, 275(29), 22121–22126. https://doi.org/10.1074/jbc.M002788200

Zhen, G., Dan, Y., Wang, R., Dou, C., Guo, Q., Zarr, M., Liu, L. N., Chen, L., Deng, R., Li, Y., Shao, Z., & Cao, X. (2021). An antibody against Siglec-15 promotes bone formation and fracture healing by increasing TRAP+ mononuclear cells and PDGF-BB secretion. Bone Research, 9(1), 47. https://doi.org/10.1038/s41413-021-00161-1

Zhuravleva, M. A., Trandem, K., & Sun, P. D. (2008). Structural Implications of Siglec-5-Mediated Sialoglycan Recognition. Journal of Molecular Biology, 375(2), 437–447. https://doi.org/10.1016/j.jmb.2007.10.009